EGFR and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and the L858R mutation, responds to first and second generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) [1, 2].